{"id":"W4288969861","doi":"10.1016/j.jtocrr.2022.100385","title":"Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; EMD Serono; Otsuka America; Ribon Therapeutics; Takeda Oncology; Mirati Therapeutics; Bayer Fund; Abbott Laboratories; Clovis Oncology; National Center for Advancing Translational Sciences; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Ipsen Biopharmaceuticals; Novartis; Celgene; Unum Therapeutics; Merck KGaA; Servier; Gilead Sciences; Sanofi; Roche; Yuhan; Merck; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Canadian Asian Studies Association; AstraZeneca; Aerie Pharmaceuticals; Pfizer; Ariad Pharmaceuticals; Boehringer Ingelheim; Amgen; Regeneron Pharmaceuticals","keywords":"Crizotinib; Refractory (planetary science); Medicine; Phase (matter); Term (time); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lung cancer; Materials science; Chemistry; Physics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01945681,0.0001235252,0.001208835,0.0001387989,0.0002049278,0.00001497119,0.00006236815,0.00008200975,0.00009991904],"category_scores_gemma":[0.01956892,0.00006954918,0.0001968132,0.0002736317,0.001172527,0.00004940917,0.0002268377,0.0006072416,1.430269e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003681049,"about_ca_system_score_gemma":0.0006927697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002939198,"about_ca_topic_score_gemma":0.00002950601,"domain_scores_codex":[0.9940901,0.00216583,0.002229062,0.00044448,0.0008377285,0.0002327751],"domain_scores_gemma":[0.9913029,0.007097328,0.0007051457,0.000402046,0.0002622636,0.0002303133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6334086,0.01242419,0.06969211,0.0005068681,0.001029995,0.001897681,0.002081964,0.000004101434,0.002411777,0.000145535,0.002283514,0.2741137],"study_design_scores_gemma":[0.7848662,0.004274228,0.2016508,0.000578321,0.0006014607,0.0003320051,0.0002519055,0.00007210505,0.0006171382,0.0005328652,0.006085119,0.0001378177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917271,0.002156807,0.000004102462,0.002276822,0.0001793111,0.002440092,0.0001391219,0.000006960156,0.00106965],"genre_scores_gemma":[0.9971562,0.001518046,0.00005703502,0.00006410634,0.0001018654,0.0001037129,0.00005880491,0.00001125412,0.0009289485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2739759,"threshold_uncertainty_score":0.9886897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2062120733192719,"score_gpt":0.5581480541043659,"score_spread":0.351935980785094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}